StockMarketWire.com - Omega Diagnostics has improved its H1 pretax profit to £0.21m, from a year-ago profit of £0.16m. Revenue was £5.7m, from £5.6m. It remains frustrated by 'inevitable' delays related to Visitect CD4. Chairman David Evans commented on Omega's outlook:

"We are optimistic about the continuing performance of our core business in the second half of this year, particularly in Food Intolerance, where we have built significant traction with new customers over recent years.

"We share your frustration with the inevitable delay that is occurring with Visitect CD4 since the last trading update.

"However, we believe we have taken the right course of action with the recent programme changes to prevent similar problems occurring with the product after its market launch.

"Despite the setback, we continue to receive feedback from the HIV/Global Health arena that convinces us that the market opportunity and outlook for CD4 remains undiminished."

Highlights:

· 200-patient evaluation of Visitect CD4 in India demonstrated acceptable performance against flow cytometry

· Engagement with experts in lateral flow diagnostics to support the transfer process and scale up

· Positive progress with 27 allergens from the allergy development programme now optimised

· Recruitment of in-house scientific team to accelerate further allergen optimisation






Story provided by StockMarketWire.com